OS Therapies Incorporated (OSTX)
NYSE: OSTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OSTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $42.00M
- Forward P/E
- 2.29
- EPS (TTM)
- -$1.08
- Dividend yield
- None
- 52-week range
- 0.58 – 2.25
- Day range
- 0.7901 – 0.8625
- Volume / Avg
- 489.73K / 722.66K
- Beta
- —
- Shares outstanding
- 52.30M
52-week range
OSTX stock today
OS Therapies (OSTX) closed at $0.803 on Nov 20, down 2.12% (-$0.0174), versus the S&P 500's 3.70% decline. At this level, OSTX sits near the bottom of its 52-week range of $0.58 to $2.25: 64.3% below the high, set on Jun 29, 2026 and 38.4% above the low. OSTX is down 42.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.0%.
OS Therapies has posted a net loss over the last twelve months (EPS of -$1.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About OS Therapies
Company profileOS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul A. Romness M.P.H.
- Headquarters
- Grasonville, MD
- Employees
- 4
- IPO year
- 2024
- Website
- ostherapies.com
Financial highlights
Full financialsOS Therapies reported a net loss of $28.8 million, compared with a loss of $8.9 million a year earlier. Diluted earnings per share came in at -$0.98.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-28.75M | $-8.88M | $-7.79M |
| EPS (diluted) | $-0.98 | $-1.28 | $-1.46 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$8.50+958.53%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.23 vs $-0.13
- Surprise
- -76.92%
OSTX news
All OSTX newsOS Therapies peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INCRIntercure Ltd. | 3.24 | -7.69% | $42.03M | vs OSTX |
| BMEABiomea Fusion Inc. | 0.5744 | -2.38% | $41.75M | vs OSTX |
| CRBPCorbus Pharmaceuticals Holdings Inc. | 2.06 | -15.40% | $42.45M | vs OSTX |
| MREOMereo BioPharma Group plc ADR | 0.26 | -5.45% | $41.52M | vs OSTX |
| ELTXElicio Therapeutics Inc. | 1.45 | -3.33% | $41.05M | vs OSTX |
| TLPHTalphera Inc. | 0.7852 | +6.25% | $40.80M | vs OSTX |
| SPROSpero Therapeutics Inc. | 0.742 | -10.20% | $43.23M | vs OSTX |
| RLYBRallybio Corporation | 15.47 | -0.32% | $43.32M | vs OSTX |
Indexes, lists and sector
OS Therapies stock FAQ
What is OS Therapies's stock price today?
OSTX last traded at $0.803 as of Nov 20, 4:00 PM EST, down 2.12% on the day. Prices are delayed at least 15 minutes.
Who is OS Therapies's CEO?
Mr. Paul A. Romness M.P.H. is the chief executive officer of OS Therapies Incorporated, which has about 4 employees.
What is the OSTX 52-week high?
The 52-week high for OSTX is $2.25 and the 52-week low is $0.58. The stock is currently 64.3% below its high.